Finder is committed to editorial independence. While we receive compensation when you click links to partners, they do not influence our content.
How to buy CytomX Therapeutics (CTMX) stocks
Learn how to easily invest in CytomX Therapeutics stocks.
CytomX Therapeutics is a biotechnology business based in the US. CytomX Therapeutics stocks (CTMX.US) are listed on the NASDAQ and all prices are listed in US Dollars. Its last market close was $7.08 – a decrease of 3.45% over the previous week. CytomX Therapeutics employs 116 staff and has a trailing 12-month revenue of around $67.6 million.
How to buy CytomX Therapeutics stock
- Choose a stock trading platform. Use our comparison table or choose from our Top Picks below.
- Open an account. Provide your personal information and sign up.
- Fund your account. Deposit funds unto your account by linking your banking information or transfer funds from another trading account.
- Search for the stock name – CTMX. Search for the stock by name or ticker symbol.
- Buy the stock. Place your order. It's that simple.
National Bank Direct Brokerage
- Commission-free trading
- Several account types available
- Access to array of research tools
CIBC Investor's Edge
- Easy to use platform
- Low fees
- Student and young investor discounts
- Access to international stock exchanges
- Low margin rates
- Powerful research tools
What's in this guide?
- Can I buy shares in CytomX Therapeutics?
- Has coronavirus impacted CytomX Therapeutics shares?
- CytomX Therapeutics shares summary
- Compare share dealing platforms
- Is CytomX Therapeutics stock a buy or sell?
- CytomX Therapeutics performance over time
- CytomX Therapeutics's financials
- How volatile are CytomX Therapeutics shares?
- Does CytomX Therapeutics pay a dividend?
- Other common questions
CytomX Therapeutics stock price (NASDAQ:CTMX)Use our graph to track the performance of CTMX stocks over time.
CytomX Therapeutics shares at a glance
|Latest market close||$1.68|
|52-week range||$1.17 - $3.02|
|50-day moving average||$1.69|
|200-day moving average||$1.78|
|Wall St. target price||$2.52|
|Dividend yield||$0 (0%)|
|Earnings per share (TTM)||$-0.96|
Buy CytomX Therapeutics stocks from these online trading platformsCompare special offers, low fees and a wide range of investment options among top trading platforms.
Note: The dollar amounts in the table below are in Canadian dollars.
Is it a good time to buy CytomX Therapeutics stock?
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
CytomX Therapeutics price performance over time
Historical closes compared with the close of $1.68 from 2023-06-01
|1 week (2023-05-26)||-3.45%|
|1 month (2023-05-02)||1.82%|
|3 months (2023-03-02)||-21.86%|
|6 months (2022-12-02)||-1.75%|
|1 year (2022-06-01)||8.39%|
|2 years (2021-05-29)||N/A|
|3 years (2020-06-02)||8.12|
|5 years (2018-06-01)||25.53|
CytomX Therapeutics financials
|Revenue TTM||$67.6 million|
|Gross profit TTM||$53.2 million|
|Return on assets TTM||-15.81%|
|Return on equity TTM||-5475.03%|
|Market capitalisation||$113.8 million|
TTM: trailing 12 months
CytomX Therapeutics share dividends
We're not expecting CytomX Therapeutics to pay a dividend over the next 12 months.
CytomX Therapeutics share price volatility
Over the last 12 months, CytomX Therapeutics's shares have ranged in value from as little as $1.17 up to $3.02. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while CytomX Therapeutics's is 0.6527. This would suggest that CytomX Therapeutics's shares are less volatile than average (for this exchange).
CytomX Therapeutics overview
CytomX Therapeutics, Inc. operates as an oncology-focused biopharmaceutical company in the United States. The company develops antibody therapeutics based on its Probody technology platform for the treatment of cancer. Its product candidates include CX-2009, an antibody drug conjugates (ADC) against CD166, which is in Phase II clinical trials for the treatment of breast cancer; CX-2029 that is in Phase II clinical trials for the treatment of squamous non-small cell lung cancer, head and neck squamous cell carcinoma, esophageal and gastro-esophageal junction cancers, and diffuse large B-cell lymphoma; CX-2051, a conditionally activated ADC that targets epithelial cell adhesion molecule-expressing epithelial cancers; and CX-801, a dually masked, conditionally activated version of Interferon alpha-2b therapy for a range of tumor types. The company also develops BMS-986288, an anti-CTLA-4 Probody drug, which is in Phase I/II clinical trials for the treatment of solid tumors; and CX-904, a conditionally activated epidermal growth factor receptor for the treatment of solid tumor. It has strategic collaborations with AbbVie Ireland Unlimited Company, Amgen, Inc. , Bristol-Myers Squibb Company, Astellas Pharma Inc.
Stocks similar to CytomX Therapeutics
CytomX Therapeutics in the news
CytomX Therapeutics to Present at the Jefferies Healthcare Conference
CytomX Therapeutics to Present at the Jefferies Healthcare Conference
CytomX Therapeutics First Quarter 2023 Earnings: Beats Expectations
Frequently asked questions
Disclaimer: This information should not be interpreted as an endorsement of futures, stocks, ETFs, options or any specific provider, service or offering. It should not be relied upon as investment advice or construed as providing recommendations of any kind. Futures, stocks, ETFs and options trading involves substantial risk of loss and therefore are not appropriate for all investors. Trading forex on leverage comes with a higher risk of losing money rapidly. Past performance is not an indication of future results. Consider your own circumstances, and obtain your own advice, before making any trades.
More on investing
How do ETFs work?
Your guide to how ETFs work and whether this type of investment is right for you.Read more…
Best stock app for beginners for 2023
The best stock trading app for beginners is easy to use and offers free trades.Read more…
How to read stock charts
Learning how to read stock charts and recognize chart patterns can unlock your success as a trader.Read more…
More guides on Finder
Best bad credit loans in Prince Edward Island
Compare some of the best bad credit loans in PEI.
Your guide to the features, interest rates and fees to expect when you apply for a short-term loan with Credito.
5 apps like Bree in Canada
Pay for unexpected bills and avoid overdrafts when you sign up for apps like Bree.
Debt Relief Canada (reliefcanada.ca) review
Take a closer look at the debt relief solutions, features and fees of Debt Relief Canada.
Desjardins Online Brokerage (Disnat) review 2023
Learn more about Desjardins Online Brokerage (Disnat) to see if it’s the right broker for you.
Guide to finding the best prepaid card in Canada in June 2023
We show you the best prepaid credit cards in Canada, whether you’re looking for a prepaid card with no fees, cash back rewards, or travel perks, or more.
How to buy Sui (SUI) in Canada
This guide provides step-by-step instructions on how to buy Sui, lists some exchanges where you can get it and provides daily price data on (SUI).
5 apps like Nyble in Canada
Compare apps like Nyble in Canada to access emergency funding.
Your guide to buying and financing a car in Canada with RightRide.
Compare bad credit car loans in BC
Your guide to bad credit car loans in BC and how to find the right financing for your needs.